HAEMONETICS CORP
About HAEMONETICS CORP
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $1.3B
- Net income
- $97.3M
- Total assets
- $2.4B
- Market cap
- $3.2B
- Gross margin
- 59.0%
- Operating margin
- 11.7%
- Net margin
- 7.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.3B
- Cost of revenue
- $546.4M
- Gross profit
- $787.6M
- Operating expenses
- $630.9M
- Operating income
- $156.7M
- Income tax
- $30.7M
- Net income
- $97.3M
- EPS (basic)
- $2.06
- EPS (diluted)
- $2.05
Balance sheet
- Total assets
- $2.4B
- Current assets
- $834.9M
- Total liabilities
- $1.6B
- Current liabilities
- $282.6M
- Shareholders’ equity
- $796.3M
Cash flow
- Operating cash flow
- $293.2M
- Investing cash flow
- -$179.5M
- Financing cash flow
- -$178.5M
- Net cash flow
- -$61.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.2B
- P/E ratio
- 36.5
- EPS (diluted)
- $2.05
- Shares outstanding
- 43.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 1991
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $97.3M in FY2026.
- Revenue grew 34% from FY2022 to FY2026.
- Gross margin of 59.0%, net margin 7.3%.
- Trading 14% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 36.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HAEMONETICS CORP.
Write a review
News about HAEMONETICS CORP
News & sentiment via Polygon.io
